Last 12 months
Inside the activity.
1 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 1 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2024 Filed Apr 2, 2024 22:32 UTC |
Riley Antony ACHIEF FINANCIAL OFFICER
|
Exercise / conversionCommon Stock | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-009859 · form4-04022024_100453.xml · nonDerivative · entry 1 Riley Antony A · CIK 0001339375 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,819 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 22:31 UTC |
Wagner Paul A.Director · SEE REMARKS
|
Exercise / conversionRestricted Stock Units · Derivative | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-009857 · form4-04022024_100445.xml · derivative · entry 3 Wagner Paul A. · CIK 0001612842 · Director · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,750 Underlying: Common Stock · 31,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. F2 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. F2 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 22:31 UTC |
Wagner Paul A.Director · SEE REMARKS
|
Tax withholdingCommon Stock | 2,453 | $0.71 | $1,735.50 |
DisclosureSEC source: 0001415889-24-009857 · form4-04022024_100445.xml · nonDerivative · entry 2 Wagner Paul A. · CIK 0001612842 · Director · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,879,174 Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 22:31 UTC |
Wagner Paul A.Director · SEE REMARKS
|
Exercise / conversionCommon Stock | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-009857 · form4-04022024_100445.xml · nonDerivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,881,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 20:09 UTC |
FINCK BARBARA KDirector
|
GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001415889-24-009032 · form4-03252024_080333.xml · derivative · entry 1 FINCK BARBARA K · CIK 0001242116 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2034-03-21 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the amended and restated 2021 Equity Incentive Plan) through each applicable vesting date, twenty five percent (25%) of the shares subject to the option shall vest on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total shares subject to the option shall vest every month thereafter such that all shares shall be fully vested on the four year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean March 21, 2024. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 20:08 UTC |
Riley Antony ACHIEF FINANCIAL OFFICER
|
GrantStock Option (right to buy) · Derivative | 350,000 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001415889-24-009031 · form4-03252024_080334.xml · derivative · entry 1 Riley Antony A · CIK 0001339375 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2034-03-21 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the amended and restated 2021 Equity Incentive Plan) through each applicable vesting date, twenty five percent (25%) of the shares subject to the option shall vest on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total shares subject to the option shall vest every month thereafter such that all shares shall be fully vested on the four year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean March 21, 2024. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 20:07 UTC |
Wagner Paul A.Director · SEE REMARKS
|
GrantStock Option (right to buy) · Derivative | 1,100,000 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001415889-24-009030 · form4-03252024_080331.xml · derivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,100,000 Underlying: Common Stock · 1,100,000 shares Expires 2034-03-21 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the amended and restated 2021 Equity Incentive Plan) through each applicable vesting date, twenty five percent (25%) of the shares subject to the option shall vest on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total shares subject to the option shall vest every month thereafter such that all shares shall be fully vested on the four year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean March 21, 2024. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:04 UTC |
Chen Hubert CSee remarks
|
Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000326 · doc4.xml · derivative · entry 3 Chen Hubert C · CIK 0001622297 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:04 UTC |
Chen Hubert CSee remarks
|
Tax withholdingCommon Stock | 3,073 | $0.82 | $2,525.08 |
DisclosureSEC source: 0001209191-24-000326 · doc4.xml · nonDerivative · entry 2 Chen Hubert C · CIK 0001622297 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,405 F2 · price: On January 1, 2024, the Reporting Person's RSUs vested. The closing price of Forte Biosciences, Inc.'s Common Stock on December 29, 2023 was the settlement price used to calculate the shares withheld. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:04 UTC |
Chen Hubert CSee remarks
|
Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000326 · doc4.xml · nonDerivative · entry 1 Chen Hubert C · CIK 0001622297 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:02 UTC |
Riley Antony AChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000319 · doc4.xml · derivative · entry 3 Riley Antony A · CIK 0001339375 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 9,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:02 UTC |
Riley Antony AChief Financial Officer
|
Tax withholdingCommon Stock | 3,841 | $0.82 | $3,156.15 |
DisclosureSEC source: 0001209191-24-000319 · doc4.xml · nonDerivative · entry 2 Riley Antony A · CIK 0001339375 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,444 F2 · price: On January 1, 2024, the Reporting Person's RSUs vested. The closing price of Forte Biosciences, Inc.'s Common Stock on December 29, 2023 was the settlement price used to calculate the shares withheld. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:02 UTC |
Riley Antony AChief Financial Officer
|
Exercise / conversionCommon Stock | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000319 · doc4.xml · nonDerivative · entry 1 Riley Antony A · CIK 0001339375 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:01 UTC |
Wagner Paul A.Director · See Remarks
|
Exercise / conversionRestricted Stock Units · Derivative | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000316 · doc4.xml · derivative · entry 3 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 31,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:01 UTC |
Wagner Paul A.Director · See Remarks
|
Tax withholdingCommon Stock | 4,109 | $0.82 | $3,376.37 |
DisclosureSEC source: 0001209191-24-000316 · doc4.xml · nonDerivative · entry 2 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,850,377 F2 · price: On January 1, 2024, the Reporting Person's RSUs vested. The closing price of Forte Biosciences, Inc.'s Common Stock on December 29, 2023 was the settlement price used to calculate the shares withheld. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:01 UTC |
Wagner Paul A.Director · See Remarks
|
Exercise / conversionCommon Stock | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000316 · doc4.xml · nonDerivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,854,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 15:56 UTC |
Wagner Paul A.Director · See Remarks
|
PurchaseCommon Stock | 10,000 | $0.75 | $7,525.00 |
DisclosureSEC source: 0001209191-23-059297 · doc4.xml · nonDerivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,823,236 F1 · price: Represents the weighted average share price of an aggregate total of 10,000 shares purchased in the price range of $0.70 to $0.77 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 14, 2023 Filed Dec 15, 2023 23:29 UTC |
Wagner Paul A.Director · See Remarks
|
PurchaseCommon Stock | 10,000 | $0.72 | $7,200.00 |
DisclosureSEC source: 0001209191-23-058867 · doc4.xml · nonDerivative · entry 2 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,813,236 F2 · price: Represents the weighted average share price of an aggregate total of 10,000 shares purchased in the price range of $0.7199 to $0.72 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 23:29 UTC |
Wagner Paul A.Director · See Remarks
|
PurchaseCommon Stock | 10,520 | $0.70 | $7,351.38 |
DisclosureSEC source: 0001209191-23-058867 · doc4.xml · nonDerivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,803,236 F1 · price: Represents the weighted average share price of an aggregate total of 10,520 shares purchased in the price range of $0.679 to $0.70 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 12, 2023 Filed Dec 13, 2023 00:30 UTC |
Wagner Paul A.Director · See Remarks
|
PurchaseCommon Stock | 4,776 | $0.65 | $3,088.16 |
DisclosureSEC source: 0001209191-23-058404 · doc4.xml · nonDerivative · entry 2 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,792,716 F2 · price: Represents the weighted average share price of an aggregate total of 4,776 shares purchased in the price range of $0.639 to $0.65 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 00:30 UTC |
Wagner Paul A.Director · See Remarks
|
PurchaseCommon Stock | 25,000 | $0.65 | $16,187.50 |
DisclosureSEC source: 0001209191-23-058404 · doc4.xml · nonDerivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,787,940 F1 · price: Represents the weighted average share price of an aggregate total of 25,000 shares purchased in the price range of $0.6199 to $0.65 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 08, 2023 Filed Dec 9, 2023 00:20 UTC |
Wagner Paul A.Director · See Remarks
|
PurchaseCommon Stock | 15,000 | $0.62 | $9,300.00 |
DisclosureSEC source: 0001209191-23-057989 · doc4.xml · nonDerivative · entry 2 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,762,940 F2 · price: Represents the weighted average share price of an aggregate total of 15,000 shares purchased in the price range of $0.6085 to $0.62 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 07, 2023 Filed Dec 9, 2023 00:20 UTC |
Wagner Paul A.Director · See Remarks
|
PurchaseCommon Stock | 36,203 | $0.58 | $21,167.89 |
DisclosureSEC source: 0001209191-23-057989 · doc4.xml · nonDerivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,747,940 F1 · price: Represents the weighted average share price of an aggregate total of 36,203 shares purchased in the price range of $0.54 to $0.60 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 22, 2023 Filed Nov 22, 2023 22:51 UTC |
Wagner Paul A.Director · See Remarks
|
PurchaseCommon Stock | 400 | $0.43 | $172.00 |
DisclosureSEC source: 0001209191-23-056522 · doc4.xml · nonDerivative · entry 4 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,711,737 Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 22:51 UTC |
Wagner Paul A.Director · See Remarks
|
PurchaseCommon Stock | 100 | $0.43 | $42.51 |
DisclosureSEC source: 0001209191-23-056522 · doc4.xml · nonDerivative · entry 3 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,711,337 Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 22:51 UTC |
Wagner Paul A.Director · See Remarks
|
PurchaseCommon Stock | 1,566 | $0.43 | $673.38 |
DisclosureSEC source: 0001209191-23-056522 · doc4.xml · nonDerivative · entry 2 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,711,237 Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 22:51 UTC |
Wagner Paul A.Director · See Remarks
|
PurchaseCommon Stock | 5,300 | $0.44 | $2,332.00 |
DisclosureSEC source: 0001209191-23-056522 · doc4.xml · nonDerivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,709,671 Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 20:29 UTC |
Chen Hubert CSee remarks
|
Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-051484 · doc4.xml · derivative · entry 3 Chen Hubert C · CIK 0001622297 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,500 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 20:29 UTC |
Chen Hubert CSee remarks
|
Tax withholdingCommon Stock | 2,593 | $0.66 | $1,716.57 |
DisclosureSEC source: 0001209191-23-051484 · doc4.xml · nonDerivative · entry 2 Chen Hubert C · CIK 0001622297 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,978 F2 · price: On October 1, 2023, the Reporting Person's RSUs vested. The closing price of Forte Biosciences, Inc.'s Common Stock on September 29, 2023 was the settlement price used to calculate the shares withheld. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 20:29 UTC |
Chen Hubert CSee remarks
|
Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-051484 · doc4.xml · nonDerivative · entry 1 Chen Hubert C · CIK 0001622297 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 20:27 UTC |
Riley Antony AChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-051480 · doc4.xml · derivative · entry 3 Riley Antony A · CIK 0001339375 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,875 Underlying: Common Stock · 9,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 20:27 UTC |
Riley Antony AChief Financial Officer
|
Tax withholdingCommon Stock | 3,241 | $0.66 | $2,145.54 |
DisclosureSEC source: 0001209191-23-051480 · doc4.xml · nonDerivative · entry 2 Riley Antony A · CIK 0001339375 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,910 F2 · price: On October 1, 2023, the Reporting Person's RSUs vested. The closing price of Forte Biosciences, Inc.'s Common Stock on September 29, 2023 was the settlement price used to calculate the shares withheld. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 20:27 UTC |
Riley Antony AChief Financial Officer
|
Exercise / conversionCommon Stock | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-051480 · doc4.xml · nonDerivative · entry 1 Riley Antony A · CIK 0001339375 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,151 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 20:26 UTC |
Wagner Paul A.Director · See Remarks
|
Exercise / conversionRestricted Stock Units · Derivative | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-051476 · doc4.xml · derivative · entry 3 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 406,250 Underlying: Common Stock · 31,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 20:26 UTC |
Wagner Paul A.Director · See Remarks
|
Tax withholdingCommon Stock | 2,453 | $0.66 | $1,623.89 |
DisclosureSEC source: 0001209191-23-051476 · doc4.xml · nonDerivative · entry 2 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,704,371 F2 · price: On October 1, 2023, the Reporting Person's RSUs vested. The closing price of Forte Biosciences, Inc.'s Common Stock on September 29, 2023 was the settlement price used to calculate the shares withheld. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 20:26 UTC |
Wagner Paul A.Director · See Remarks
|
Exercise / conversionCommon Stock | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-051476 · doc4.xml · nonDerivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,706,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 21:55 UTC |
Brun Scott C.Director
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-23-050196 · doc4.xml · derivative · entry 1 Brun Scott C. · CIK 0001863614 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-09-19 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean September 19, 2023. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 21:48 UTC |
Doberstein Stephen KDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-23-050190 · doc4.xml · derivative · entry 1 Doberstein Stephen K · CIK 0001480111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-09-19 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean September 19, 2023. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 21:54 UTC |
Williams Donald AllenDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-23-050195 · doc4.xml · derivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-09-19 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean September 19, 2023. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 21:53 UTC |
Kornfeld StevenDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-23-050194 · doc4.xml · derivative · entry 1 Kornfeld Steven · CIK 0001814653 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-09-19 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean September 19, 2023. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 21:52 UTC |
GRYSKA DAVID WDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-23-050193 · doc4.xml · derivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-09-19 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean September 19, 2023. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 21:50 UTC |
FINCK BARBARA KDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-23-050192 · doc4.xml · derivative · entry 1 FINCK BARBARA K · CIK 0001242116 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-09-19 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean September 19, 2023. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 21:49 UTC |
Eichenfield LawrenceDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-23-050191 · doc4.xml · derivative · entry 1 Eichenfield Lawrence · CIK 0001814892 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-09-19 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean September 19, 2023. Read SEC document |
| July 31, 2023 Filed Aug 2, 2023 22:03 UTC |
Kornfeld StevenDirector
|
GrantCommon Stock | 99,009 | $1.01 | $99,999.09 |
DisclosureSEC source: 0001209191-23-044286 · doc4.xml · nonDerivative · entry 1 Kornfeld Steven · CIK 0001814653 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,009 Read SEC document |
| July 31, 2023 Filed Aug 2, 2023 22:02 UTC |
Williams Donald AllenDirector
|
GrantCommon Stock | 59,405 | $1.01 | $59,999.05 |
DisclosureSEC source: 0001209191-23-044285 · doc4.xml · nonDerivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,405 Read SEC document |
| July 31, 2023 Filed Aug 2, 2023 22:00 UTC |
GRYSKA DAVID WDirector
|
GrantCommon Stock | 148,514 | $1.01 | $149,999.14 |
DisclosureSEC source: 0001209191-23-044284 · doc4.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,514 Read SEC document |
| July 31, 2023 Filed Aug 2, 2023 21:58 UTC |
Chen Hubert CSee remarks
|
GrantCommon Stock | 74,257 | $1.01 | $74,999.57 |
DisclosureSEC source: 0001209191-23-044282 · doc4.xml · nonDerivative · entry 1 Chen Hubert C · CIK 0001622297 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,071 Read SEC document |
| July 31, 2023 Filed Aug 2, 2023 21:57 UTC |
Riley Antony AChief Financial Officer
|
GrantCommon Stock | 148,514 | $1.01 | $149,999.14 |
DisclosureSEC source: 0001209191-23-044281 · doc4.xml · nonDerivative · entry 1 Riley Antony A · CIK 0001339375 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,776 F1 · balance_after: Includes 3,500 shares of Common Stock acquired July 3, 2023 under Forte Biosciences, Inc.'s 2017 Employee Stock Purchase Plan. Read SEC document |
| July 31, 2023 Filed Aug 2, 2023 21:56 UTC |
Wagner Paul A.Director · See Remarks
|
GrantCommon Stock | 247,524 | $1.01 | $249,999.24 |
DisclosureSEC source: 0001209191-23-044280 · doc4.xml · nonDerivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,675,574 Read SEC document |
| July 01, 2023 Filed Jul 5, 2023 20:08 UTC |
Chen Hubert CSee remarks
|
Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-040978 · doc4.xml · derivative · entry 3 Chen Hubert C · CIK 0001622297 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.